Redeye: CombinedX - Soft Q2, We Foresee a Rebound in H2
Redeye retains its optimistic view on CombinedX despite lowering its Base Case and forecasts slightly following a soft Q2 report. We believe the issues hurting Q2 primarily are temporary and foresee a rebound in H2.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/